Clinical trials: Parkinsons Disease With Dementia
Parkinson Disease
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.
- Trial name
- NCT06309147
- Testing
- BMS-9894923
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allyx Therapeutics
Alzheimer's Disease, Parkinson's Disease
Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration
The aim of this study is to compare personality and social cognition changes, including emotion detection and self-awareness, and neuroanatomical correlates in patients, and how that affects the caregiver-patient relationship.
- Conditions
- Alzheimer's Disease, Parkinson's Disease, Frontotemporal Lobar Degeneration
- Trial name
- NCT02964611
- Testing
- Observational Study
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Alzheimer's Disease, Amyotrophic Lateral Sclerosis
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease
- Trial name
- NCT02750982
- Testing
- Laughter Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Parkinsons Disease With Dementia
A Study to Evaluate Temporary Blood Brain Barrier Disruption in Patients With Parkinson's Disease Dementia
The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and initial efficacy of this treatment (temporary disruption of the BBB) using this ExAblate Model 4000 Type 2…
- Trial name
- NCT03608553
- Testing
- MR Guided Focused Ultrasound
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- InSightec
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Parkinson Disease, Parkinsons Disease With Dementia
A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Parkinson's Disease.
- Conditions
- Parkinson Disease, Parkinsons Disease With Dementia, Parkinson-Dementia Syndrome, Parkinson Disease 2
- Trial name
- NCT04148326
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Dementia, Dementia With Lewy Bodies
Monitoring Anti-Dementia Drugs by Serum Levels
The main objective of the MONANTI study is twofold: Firstly, to determine the serum concentration (SC) the anti-dementia drugs donepezil and memantine in a broadly defined clinical population of patients suffering from dementia…
- Conditions
- Dementia, Dementia With Lewy Bodies, Dementia in Parkinsons Disease, Dementia Alzheimers
- Trial name
- MONANTI (NCT04117178)
- Testing
- Donepezil, Memantine, Measurement of serum level of anti-dementia drug
- Where
- Denmark
- Volunteers
- 132 people
- Sponsor
- Zealand University Hospital
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease, Dementia With Lewy Bodies
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Study goal: The goal of this prospective head to head comparison is to evaluate the effectiveness of [18F]-MFBG PET in assessing cardiac innervation, comparing it with [123I]-MIBG SPECT The study's primary focus is on…
- Conditions
- Parkinson Disease, Dementia With Lewy Bodies, MSA - Multiple System Atrophy, Alzheimer Disease
- Trial name
- NCT06120049
- Testing
- [18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT
- Where
- 2 sites in Belgium
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Parkinson Disease Dementia
OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.
- Trial name
- NCT04575259
- Testing
- ANAVEX2-73
- Where
- 10 sites in Australia, Spain
- Volunteers
- 132 people
- Sponsor
- Anavex Life Sciences Corp.
Parkinson Disease, Parkinson Disease Dementia
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia.
- Trial name
- BUTTER2 (NCT07154511)
- Testing
- Tributyrin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Prabesh Kanel
Dementia in Parkinson's Disease
Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's.
We will perform a pilot study to evaluate the effectiveness of human NBM DBS at improving cognitive deficits in PD patients referred and eligible for conventional DBS treatment for coexisting motor impairments.
- Trial name
- NCT01701544
- Testing
- NBM DBS
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- University College, London
Parkinson Disease
Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology
This study aimed to determine the efficacy of amyloid clearance of lecanemab in patients with Parkinson's disease (PD) with amyloid co-pathology.
- Trial name
- NCT07544953
- Testing
- Lecanemab, Lecanemab non-administration group
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Parkinson Disease, Parkinson Disease Dementia
Parkinson's Disease and Movement Disorders Clinical Database
The research database contains demographic and family history information, longitudinal information on the clinical symptoms, neuropsychological profile and treatments, stored biological samples, and brain images of patients with…
- Conditions
- Parkinson Disease, Parkinson Disease Dementia, Lewy Body Parkinson Disease, Lewy Body Dementia With Behavioral Disturbance
- Trial name
- NCT04997642
- Testing
- neuropsychiatric and cognitive testing questionnaires
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of Pennsylvania
Parkinson Disease, Osteoporosis
Trial of Parkinson's And Zoledronic Acid
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and…
- Conditions
- Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism
- Trial name
- TOPAZ (NCT03924414)
- Testing
- Zoledronic Acid 5Mg/Bag 100Ml Inj
- Where
- 77 sites in United States
- Volunteers
- 2,721 people
- Sponsor
- California Pacific Medical Center Research Institute
Huntington's Disease, Parkinson's Disease
Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon
The proposed study is a double-blind, placebo controlled pilot study of HD, PD, and DLB subjects with sleep disturbances. This study is designed to determine the effects of 4 weeks Ramelteon treatment on the sleep patterns of…
- Conditions
- Huntington's Disease, Parkinson's Disease, Dementia With Lewy Bodies, Sleep Disorders
- Trial name
- NCT00907595
- Testing
- Ramelteon
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Alpha-Synucleinopathy, Parkinson's Disease
Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain
The overall goal of this protocol is to evaluate [18F]MNI-1216 (also known as [18F]ACI-12589) as an α-synuclein targeted radiopharmaceutical in 3 parts as follows: Part 1: first in human (FiH) imaging Optional Part 2: expansion…
- Conditions
- Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
- Trial name
- NCT06445465
- Testing
- [18F]MNI-1216
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro
Mild Cognitive Impairment, Mild Dementia
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
- Trial name
- NCT04148391
- Testing
- NYX-458
- Where
- 26 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aptinyx
Alzheimer Disease, Parkinson Disease
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
The primary objective of this protocol is to examine [18F]MNI-1126 as a tool to assess synaptic density loss.
- Conditions
- Alzheimer Disease, Parkinson Disease, Healthy Volunteers
- Trial name
- NCT03587649
- Testing
- [18F]MNI-1126
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro